Search

Background: Lung Adenocarcinoma (LUAD) is the leading cause of death from lung cancer. Cuproptosis is the latest discovered way of programmed cell death, and Cuproptosis-Related Gene (CRG) is associated with the risk of LUAD. At present, there are few research of LUAD and Cuproptosis focuses on Long non-coding RNA (LncRNA). As genomics advances, LncRNA emerges as a potential target for understanding tumor progression and prognosis, offering prospects for biological targeted therapy. Therefore, this study provides new biomarkers and therapeutic targets for LUAD from the perspective of LncRNA. Methods: Gene expression, clinical outcome and gene mutation data of LUAD patients were downloaded from TCGA database. Spearman correlation was used to analyze the correlation between LncRNA and CRG. Univariate Cox, multivariate Cox and LASSO Cox regression analysis were used to construct a prognostic model of Cuproptosis-LncRNAs. GO and KEGG enrichment and immune function analysis were performed on differentially expressed genes between different risk groups. Then, immune escape analysis was performed on LUAD patients with different TIDE score. Finally, drug sensitivity analysis was performed on these differentially expressed genes. Results: A total of 2244 Cuproptosis-LncRNAs were found. Through the application of univariate Cox regression analysis, multivariate Cox regression analysis, and LASSO Cox regression analysis, a prognostic model was developed, integrating 15 Cuproptosis-LncRNAs to assess the risk of mortality. Following that, the model underwent assessment through risk score analysis, Kaplan-Meier survival analysis, risk distribution, and evaluation of survival outcomes. The results revealed an AUC value of 0.755 for the model, surpassing the AUC of other clinical pathological features. The results of KEGG analysis showed that the differentially expressed genes in different model groups were mainly involved in Amoebiasis, Fat digestion and absorption, and other signaling pathways. The results of TMB showed that the prognostic model of TMB combined with risk score could well evaluate the prognosis of patients. The TIDE scores did not exhibit a notable distinction between the two risk models. Analysis of drug sensitivity revealed that individuals in the low-risk category demonstrated greater responsiveness to 5-Fluorouracil, Axitinib, Bexarotene, and other drugs compared to those in the high-risk group. Conclusion: Our research offers a valuable reference for predicting the prognosis of LUAD, contributing to a better understanding of the future elucidation of the process and mechanism of Cuproptosis-LncRNAs in LUAD. [ABSTRACT FROM AUTHOR]

Aim: The study aims to systematically assess the efficacy and safety of Gegen Qinlian decoction in the treatment of type 2 diabetes mellitus. Methods: We systematically searched a total of nine databases from the time of creation to 20 March 2023. The quality of the literature was assessed using the risk of bias assessment tool in the Cochrane Handbook. RevMan 5. 3 and Stata 14.0 were applied to conduct meta-analysis. Results: A total of 17 studies, encompassing 1,476 patients, were included in the study. Gegen Qinlian decoction combined with conventional treatment was found to significantly reduce FBG (MD = -0.69 mmol/L, 95% CI -0.84 to -0.55, p < 0.01; I2 = 67%, p<0.01), 2hPG (MD = -0.97 mmol/L, 95% CI -1.13 to -0.81, p < 0.01; I2 = 37%, p=0.09), HbA1c (MD = -0.65%, 95% CI -0.78 to -0.53, p < 0.01; I2 = 71%, p<0.01), TC (MD = -0.51 mmol/L, 95% CI -0.62 to -0.41, p < 0.01; I2 = 45%, p=0.09), TG (MD = -0.17mmol/L, 95% CI -0.29 to -0.05, p < 0.01; I2 = 78%, p<0.01), LDL-C (MD = -0.38mmol/L, 95% CI -0.53 to -0.23, p < 0.01; I2 = 87%, p<0.01), HOMA-IR (SMD = -1.43, 95% CI -2.32 to -0.54, p < 0.01; I2 = 94%, p<0.01), and improved HDL-C (MD = 0.13 mmol/L, 95% CI 0.09-0.17, p < 0.01; I2 = 30%, p=0.24). Only three studies explored the differences in efficacy between GQD alone and conventional treatment in improving glucose-lipid metabolism and insulin resistance, and some of the outcome indicators, such as 2hPG and HDL-C, were examined in only one study. Therefore, the effect of GQD alone on glucose-lipid metabolism and insulin resistance cannot be fully determined, and more high-quality studies are needed to verify it. Publication bias analysis revealed no bias in the included studies. Conclusion: Gegen Qinlian Decoction has certain efficacy and safety in enhancing glycolipid metabolism and alleviating insulin resistance, potentially serving as a complementary therapy for type 2 diabetes mellitus. Rigorous, large-sample, multicenter RCTs are needed to verify this. [ABSTRACT FROM AUTHOR]